BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wijarnpreecha K, Li F, Xiang Y, Xu X, Zhu C, Maroufy V, Wang Q, Tao W, Dang Y, Pham HA, Zhou Y, Li J, Zhang X, Xu H, Taner CB, Yang L, Tao C. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Aliment Pharmacol Ther 2021;54:481-92. [PMID: 34224163 DOI: 10.1111/apt.16490] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang Y, Li M, Luo J, Yu H, Tian H, Wang X. Non‐hemodynamic effects: Repurposing of nonselective beta‐blockers in cirrhosis? Portal Hypertension & Cirrhosis 2022;1:153-156. [DOI: 10.1002/poh2.22] [Reference Citation Analysis]
2 Gananandan K, Mookerjee R, Jalan R. Use of Non-selective Beta blockers in Decompensated Cirrhosis and ACLF. Curr Hepatology Rep 2022;21:29-36. [DOI: 10.1007/s11901-022-00584-2] [Reference Citation Analysis]
3 Dunne PDJ, Young D, Chuah CS, Hayes PC, Tripathi D, Leithead J, Smith LA, Gaya DR, Forrest E, Stanley AJ. Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial. Aliment Pharmacol Ther 2022;55:1581-7. [PMID: 35322892 DOI: 10.1111/apt.16901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Altshuler E, Aryan M, Kallumkal G, Gao H, Wilson J, Ouni A, De Leo E, Hanayneh W, Pan K. Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma. Hepatic Oncology 2022;9:HEP43. [DOI: 10.2217/hep-2021-0010] [Reference Citation Analysis]
5 Tapper EB, Ufere NN, Huang DQ, Loomba R. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther 2022;55:1099-115. [PMID: 35235219 DOI: 10.1111/apt.16831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lelou E, Corlu A, Nesseler N, Rauch C, Mallédant Y, Seguin P, Aninat C. The Role of Catecholamines in Pathophysiological Liver Processes. Cells 2022;11:1021. [DOI: 10.3390/cells11061021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Li F, Rasmy L, Xiang Y, Feng J, Du J, Aguilar D, Dhoble A, Wang Q, Niu S, Hu X, Dang Y, Zhang X, Xie Z, Nian Y, He J, Zhou Y, Abdelhameed A, Bian J, Zhi D, Tao C. AI-aided dynamic prediction of bleeding and ischemic risk after coronary stenting and subsequent DAPT.. [DOI: 10.1101/2022.02.05.22270508] [Reference Citation Analysis]
8 Cheng HY, Lin HC, Lin HL, Uang YS, Keller JJ, Wang LH. Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation. Front Pharmacol 2021;12:805318. [PMID: 35069216 DOI: 10.3389/fphar.2021.805318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wijarnpreecha K, Li F, Dang Y, Taner CB, Yang L, Tao C. Letter: hepatocellular carcinoma risk in patients with non-selective beta blockers-authors' reply. Aliment Pharmacol Ther 2021;54:1095-6. [PMID: 34564885 DOI: 10.1111/apt.16598] [Reference Citation Analysis]
10 Huang DQ, Nguyen MH. Letter: hepatocellular carcinoma risk in patients with non-selective beta blockers. Aliment Pharmacol Ther 2021;54:1093-4. [PMID: 34564887 DOI: 10.1111/apt.16576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wijarnpreecha K, Li F, Taner CB, Yang L, Tao C. Editorial: when to start carvedilol in cirrhosis-time to reconsider? Authors' reply. Aliment Pharmacol Ther 2021;54:728-9. [PMID: 34379839 DOI: 10.1111/apt.16526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gillespie S, Hayes PC. Editorial: when to start carvedilol in cirrhosis—time to reconsider? Aliment Pharmacol Ther 2021;54:726-7. [DOI: 10.1111/apt.16512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]